"My name is Ellen Linnea Freese Ballegaard and I'm a medical doctor and a PhD student at the Department of Nephrology at the Copenhagen University Hospital of Rigshospitalet in Copenhagen. And today we're going to talk about my registry based study regarding cardiorenal outcomes and the development and treatment from 2011 to 2023 in incident per chronic kidney disease patients.

We looked at the guideline recommendations for treatment with this lipid lowering medication, renin angiotensin system inhibitors and SGLT2 inhibitors. And we saw an increase in the probability of treatment with SGLT2 inhibitors and renin angiotensin system inhibitors. While the probability of treatment with lipid lowering agents was unchanged during the study period. So by the end the probability of treatment with SGLT2 inhibitors was around 10%, lipid lowering treatment was around 60 and the renin angiotensin system inhibitor treatment was around 70% one year probability of the treatment.

The challenge is and have been shown in many studies that treating patients with chronic kidney disease is quite complex but because they have many comorbidities, so even in specialised clinical care settings, implementing guideline recommendations can be quite challenging. And it's only 3% of the patients that are cared for in a specialised care setting. So it's a great challenge to communicate that the patients who are cared for by general practitioners should also adhere to guideline recommendations. So yeah, that is the great challenge.

Well we were actually quite positive to see that to a great extent treatment was in accordance with guideline recommendations, especially when the focus was on patients who were not cared for at the hospital. Also we saw that one third of the patients had had a urine albumin creatinine ratio measurement, which was very positive and shows that there is attention to patients with chronic kidney disease. But of course we need to increase that intention to improve the quality of treatment.

I think that as the prevalence of chronic kidney disease is increasing and chronic kidney disease is predicted to be the fifth most prevalent disease in 2040, we need to really increase the attention by general practitioners to the guideline recommendations, to strengthen the care of our chronic kidney disease patients who are not cared for at the hospital and to prevent them from even coming to the hospital, by slowing the progression of their chronic kidney disease.”